表紙
市場調查報告書

人體微生物群的全球市場 - 至2027年的預測:益生元,益生菌,食品,醫療食,醫藥品

Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology - Global Forecast to 2027

出版商 MarketsandMarkets 商品編碼 312652
出版日期 內容資訊 英文 129 Pages
訂單完成後即時交付
價格
Back to Top
人體微生物群的全球市場 - 至2027年的預測:益生元,益生菌,食品,醫療食,醫藥品 Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology - Global Forecast to 2027
出版日期: 2019年09月03日內容資訊: 英文 129 Pages
簡介

全球人體微生物群市場預計將從2024年的9億4200萬美元擴大到2027年17億3100萬美元的規模。市場在2024年∼2027年間,預測將以年複合成長率 (CAGR) 22.5%的速度成長。

本報告提供全球人體微生物群 市場相關調查分析,市場概要,產業趨勢,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 人微生物叢:市場概要
  • 人微生物叢市場:各產品
  • 歐洲 - 人微生物叢市場:各產品、用途
  • 人微生物叢市場:各疾病

第5章 市場概要

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題

第6章 人微生物叢的全球市場:各產品

  • 簡介
  • 益生菌
  • 益生元
  • 食品
  • 醫療食
  • 診斷檢驗
  • 醫藥品

第7章 人微生物叢的全球市場:各用途

  • 簡介
  • 治療
  • 診斷

第8章 人微生物叢的全球市場:各疾病

  • 簡介
  • 感染疾病
  • 發炎性疾病
  • 內分泌、代謝異常
  • 癌症
  • 其他

第9章 人微生物叢的全球市場:各技術

  • 簡介
  • 基因學
  • 蛋白質體學
  • 代謝體學

第10章 人微生物叢的全球市場:各地區

  • 簡介
  • 歐洲
  • 北美
  • 亞太地區
  • 其他

第11章 競爭情形

  • 概要
  • 競爭領導製圖
  • 競爭情形、趨勢

第12章 企業簡介

  • ENTEROME BIOSCIENCE
  • SERES THERAPEUTICS
  • 4D PHARMA PLC
  • UBIOME, INC.
  • E.I. DU PONT DE NEMOURS AND COMPANY
  • SYNLOGIC
  • SECOND GENOME
  • VEDANTA BIOSCIENCES, INC.
  • FERRING PHARMACEUTICALS
  • EVELO BIOSCIENCES, INC.
  • VITHERA PHARMACEUTICALS, INC.
  • BIOMX
  • LNC THERAPEUTICS

第13章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BT 2711

"Increased focus on human microbiome therapy development to drive the growth of this market."

The global human microbiome market is projected to reach USD 1,731 million in 2027 from 942 million in 2024, at CAGR of 22.5 % during the forecast period. Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.

"Prebiotics are expected to grow at the highest CAGR during the forecast period."

Based on product, the human microbiome market is segmented into probiotics, prebiotics, foods, medical foods, diagnostic tests, and drugs. Of these, probiotics are expected to grow at the highest CAGR during the forecast period. The large share of this market segment can primarily be attributed to growing awareness about probiotics as a potential therapy and the credibility of health claims and safety of probiotics.

"The diagnostics segment is expected to grow at the highest CAGR during the forecast period."

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR in the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.

"The infectious diseases segment is expected to grow at the highest CAGR during the forecast period."

The infectious disease segment is expected to account for the largest share of the global human microbiome market in 2024. This is due to increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting the microbiome modulators for infectious diseases, which accounts for 40-50 products that are currently in the pipeline.

"The genomics segment is expected to grow at the highest CAGR during the forecast period."

On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to grow at the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market. Newly emerging disciplines such as metagenomics help researchers to uncover what microorganisms are present in a sample, to determine their relative abundance and gain insights on their biochemical pathways.

"North America to grow at the highest CAGR during the forecast period."

In the human microbiome market, North America is estimated to grow at the highest CAGR during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.

In-depth interviews were conducted with Chief Executive Officers (CEOs), marketing directors, other innovation and technology directors, and executives from various key organizations operating in the human microbiome market.

  • By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 30%
  • By Designation: C-level Executives: 27%, Directors: 18%, and Others: 55%
  • By Region: North America: 50%, Europe: 20%, APAC: 15%, and RoW: 15%

The human microbiome market comprises major players such as Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma (UK). The study includes an in-depth competitive analysis of these key players in the patient market, along with their company profiles, recent developments, and key market strategies.

Research Coverage:

The market study covers the human microbiome market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, based on the product, application, disease, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS COVERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY SOURCES
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 HUMAN MICROBIOME: MARKET OVERVIEW
  • 4.2 HUMAN MICROBIOME MARKET, BY PRODUCT
  • 4.3 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2022)
  • 4.4 HUMAN MICROBIOME MARKET, BY DISEASE

5 MARKET OVERVIEW

  • 5.1 MARKET DYNAMICS
    • 5.1.1 DRIVERS
      • 5.1.1.1 Increased focus on human microbiome therapy development
      • 5.1.1.2 Human microbiome as a validated target for drug development
      • 5.1.1.3 Human microbiome for early disease detection and diagnosis
    • 5.1.2 RESTRAINTS
      • 5.1.2.1 Lack of expertise and detailed research
      • 5.1.2.2 Barriers in proving the causal link between dysbiosis and disease
    • 5.1.3 OPPORTUNITIES
      • 5.1.3.1 Investigational new drug requirements for fecal microbiota
      • 5.1.3.2 Increasing collaborations
    • 5.1.4 CHALLENGES
      • 5.1.4.1 Government regulations

6 HUMAN MICROBIOME MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 PROBIOTICS
    • 6.2.1 ONGOING RESEARCHES ON PROBIOTICS PROMOTING ITS CREDIBILITY IN HEALTH CLAIMS AND SAFETY
  • 6.3 PREBIOTICS
    • 6.3.1 DEVELOPMENT OF TARGETED PREBIOTICS TOWARDS ENHANCING GUT MICROBIOTA IS THE KEY GROWTH DRIVER FOR THIS SEGMENT
  • 6.4 FOODS
    • 6.4.1 RISING AWARENESS OF MICROBIOTA-TARGETED DIETS IS DRIVING MARKET GROWTH
  • 6.5 MEDICAL FOODS
    • 6.5.1 USAGE OF TARGETED MICROBIOME FOR TREATING METABOLIC SYNDROME IS EXPECTED TO DRIVE THIS SEGMENT
  • 6.6 DIAGNOSTIC TESTS
    • 6.6.1 INCREASED CONSUMER AWARENESS ABOUT MICROBIOME-BASED TESTS, WHICH PROVIDE PREVENTATIVE HEALTH INSIGHTS TO DRIVE THIS SEGMENT
  • 6.7 DRUGS
    • 6.7.1 INCREASING NUMBER OF MICROBIOME-BASED DRUG PIPELINE IS THE KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT

7 HUMAN MICROBIOME MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
  • 7.2 THERAPEUTICS
    • 7.2.1 AVAILABILITY OF FUNDING FOR RESEARCH AND GROWING EVIDENCE FOR EFFECTIVENESS OF MICROBIOME IS FAVORING MARKET GROWTH
  • 7.3 DIAGNOSTICS
    • 7.3.1 INCREASING FOCUS OF BIOTECH COMPANIES ON LIFE SCIENCE RESEARCH IS SUPPORTING MARKET GROWTH

8 HUMAN MICROBIOME MARKET, BY DISEASE

  • 8.1 INTRODUCTION
  • 8.2 INFECTIOUS DISEASES
    • 8.2.1 INCREASING R&D INTO TARGETED ANTI-BACTERIAL PRODUCTS WILL DRIVE MARKET GROWTH
  • 8.3 INFLAMMATORY DISEASES
    • 8.3.1 SIDE-EFFECTS OF IMMUNOSUPPRESSANTS HAVE PROMPTED DEMAND FOR BETTER THERAPEUTICS
  • 8.4 ENDOCRINE & METABOLIC DISORDERS
    • 8.4.1 GUT MICROBIOTA HAS BECOME A POTENTIAL NUTRITIONAL AND PHARMACOLOGICAL TARGET FOR OBESITY MANAGEMENT
  • 8.5 CANCER
    • 8.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN THE TREATMENT OF CANCER POLYPS
  • 8.6 OTHER DISEASES

9 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY

  • 9.1 INTRODUCTION
  • 9.2 GENOMICS
    • 9.2.1 SEQUENCING
      • 9.2.1.1 The declining cost of next-generation sequencing is driving the growth of this market
    • 9.2.2 OTHER GENOMICS TECHNOLOGIES
  • 9.3 PROTEOMICS
    • 9.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMICS TECHNOLOGIES TO DRIVE MARKET GROWTH
  • 9.4 METABOLOMICS
    • 9.4.1 METABOLOMICS HAS SEVERAL ADVANTAGES OVER GENOMICS AND PROTEOMICS IN MICROBIOME RESEARCH

10 HUMAN MICROBIOME MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 EUROPE
    • 10.2.1 EXTENDED APPLICATIONS FOR MICROBIOME TO THERAPEUTIC AREAS TO BOOST THE ADOPTION OF MICROBIOME-BASED PRODUCTS IN EUROPE
  • 10.3 NORTH AMERICA
    • 10.3.1 US
      • 10.3.1.1 Rising of investment by NIH to support microbiome research is driving the market growth in the US
    • 10.3.2 CANADA
      • 10.3.2.1 The Canadian Microbiome Initiative 2 is supporting the market growth in the country
  • 10.4 ASIA PACIFIC
    • 10.4.1 INCREASING FOCUS ON MICROBIOME RESEARCH TO DRIVE MARKET GROWTH
  • 10.5 REST OF THE WORLD (ROW)
    • 10.5.1 INCREASING INCIDENCE OF CANCER TO DRIVE THE DEVELOPMENT OF MICROBIOME-BASED DIAGNOSTIC TOOLS IN ROW

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 COMPETITIVE LEADERSHIP MAPPING (2018)
    • 11.2.1 INNOVATORS
    • 11.2.2 EMERGING COMPANIES
  • 11.3 COMPETITIVE SITUATION AND TRENDS
    • 11.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
    • 11.3.2 ACQUISITIONS AND MERGERS
    • 11.3.3 PRODUCT LAUNCHES
    • 11.3.4 EXPANSIONS

12 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 12.1 ENTEROME BIOSCIENCE
  • 12.2 SERES THERAPEUTICS
  • 12.3 4D PHARMA PLC
  • 12.4 UBIOME, INC.
  • 12.5 E.I. DU PONT DE NEMOURS AND COMPANY
  • 12.6 SYNLOGIC
  • 12.7 SECOND GENOME
  • 12.8 VEDANTA BIOSCIENCES, INC.
  • 12.9 FERRING PHARMACEUTICALS
  • 12.10 EVELO BIOSCIENCES, INC.
  • 12.11 VITHERA PHARMACEUTICALS, INC.
  • 12.12 BIOMX
  • 12.13 LNC THERAPEUTICS

Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1 HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
  • TABLE 2 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2021-2027 (USD MILLION)
  • TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY 2021-2027 (USD MILLION)
  • TABLE 4 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2021-2027 (USD MILLION)
  • TABLE 5 NORTH AMERICA: PREBIOTICS MARKET, BY COUNTRY 2021-2027 (USD MILLION)
  • TABLE 6 HUMAN MICROBIOME MARKET FOR FOODS, BY REGION, 2021-2027 (USD MILLION)
  • TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR FOODS, BY COUNTRY 2021-2027 (USD MILLION)
  • TABLE 8 HUMAN MICROBIOME MARKET FOR MEDICAL FOODS, BY REGION, 2021-2027 (USD MILLION)
  • TABLE 9 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR MEDICAL FOODS, BY COUNTRY 2021-2027 (USD MILLION)
  • TABLE 10 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 11 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY 2019-2027 (USD MILLION)
  • TABLE 12 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2021-2027 (USD MILLION)
  • TABLE 13 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY 2021-2027 (USD MILLION)
  • TABLE 14 HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 15 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 17 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 18 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 19 HUMAN MICROBIOME MARKET, BY DISEASE, 2019-2027 (USD MILLION)
  • TABLE 20 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
  • TABLE 21 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 22 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 23 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR INFLAMMATORY DISEASES
  • TABLE 24 HUMAN MICROBIOME MARKET FOR INFLAMMATORY DISEASES, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFLAMMATORY DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 26 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR METABOLIC DISEASES
  • TABLE 27 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 28 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 29 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 30 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 31 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 32 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2019-2027 (USD MILLION)
  • TABLE 33 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 34 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 35 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 36 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 37 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 2017-2024 (USD MILLION)
  • TABLE 38 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 39 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 40 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMICS TECHNOLOGIES, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 41 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMICS TECHNOLOGIES, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 42 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR PROTEOMICS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 43 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR PROTEOMICS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 44 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR METABOLOMICS, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 45 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR METABOLOMICS, BY COUNTRY, 2017-2024 (USD MILLION)
  • TABLE 46 HUMAN MICROBIOME MARKET, BY REGION, 2019-2027 (USD MILLION)
  • TABLE 47 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY REGION, 2017-2024 (USD MILLION)
  • TABLE 48 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
  • TABLE 49 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 50 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2019-2027 (USD MILLION)
  • TABLE 51 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 52 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2017-2024 (USD MILLION)
  • TABLE 53 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
  • TABLE 54 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2019-2027 (USD MILLION)
  • TABLE 56 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 57 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 58 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
  • TABLE 59 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 60 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2019-2027 (USD MILLION)
  • TABLE 61 US: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 62 US: HUMAN MICROBIOME RESEARCH SPENDING FOR GENOMICS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 63 INDICATIVE LIST OF PROJECTS ON HUMAN MICROBIOME IN 2018
  • TABLE 64 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
  • TABLE 65 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 66 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2019-2027 (USD MILLION)
  • TABLE 67 CANADA: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 68 CANADA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
  • TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 71 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2019-2027 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 74 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 2019-2027 (USD MILLION)
  • TABLE 75 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION, 2019-2027 (USD MILLION)
  • TABLE 76 ROW: HUMAN MICROBIOME MARKET, BY DISEASE, 2019-2027 (USD MILLION)
  • TABLE 77 ROW: HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2017-2024 (USD MILLION)
  • TABLE 78 ROW: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 79 AGREEMENTS AND PARTNERSHIPS, 2016-2019
  • TABLE 80 ACQUISITIONS AND MERGERS 2016-2019
  • TABLE 81 PRODUCT LAUNCHES, 2016-2019
  • TABLE 82 EXPANSIONS, 2016-2019

LIST OF FIGURES

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BOTTOM-UP APPROACH
  • FIGURE 4 TOP DOWN APPROACH
  • FIGURE 5 DATA TRIANGULATION METHODOLOGY
  • FIGURE 6 HUMAN MICROBIOME MARKET SHARE, BY PRODUCT, 2022
  • FIGURE 7 HUMAN MICROBIOME MARKET, BY APPLICATION, 2022
  • FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE HUMAN MICROBIOME MARKET
  • FIGURE 9 INCREASING FOCUS ON HUMAN MICROBIOME THERAPY DEVELOPMENT TO DRIVE THE GROWTH OF THIS MARKET
  • FIGURE 10 PROBIOTICS DOMINATED THE HUMAN MICROBIOME PRODUCTS MARKET IN 2022
  • FIGURE 11 INFECTIOUS DISEASES TO REGISTER THE HIGHEST GROWTH IN THE MARKET, BY DISEASE, DURING THE FORECAST PERIOD
  • FIGURE 12 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 NUMBER OF MICROBIOME MODULATORS IN ACTIVE DEVELOPMENT, BY YEAR, 2011-2017
  • FIGURE 14 GEOGRAPHIC SNAPSHOT: NORTH AMERICA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 15 EUROPE TO DOMINATE THE HUMAN MICROBIOME MARKET DURING THE PERIOD OF 2024 TO 2027
  • FIGURE 16 ASIA PACIFIC HUMAN MICROBIOME MARKET: SNAPSHOT
  • FIGURE 17 HUMAN MICROBIOME MARKET (GLOBAL), COMPETITIVE LEADERSHIP MAPPING, 2018
  • FIGURE 18 SERES THERAPEUTICS: COMPANY SNAPSHOT (2018)
  • FIGURE 19 4D PHARMA PLC: COMPANY SNAPSHOT (2018)
  • FIGURE 20 E.I. DU PONT DE NEMOURS AND COMPANY: COMPANY SNAPSHOT (2018)
  • FIGURE 21 SYNLOGIC: COMPANY SNAPSHOT (2018)
  • FIGURE 22 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2018)
Back to Top